These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 8383266

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
    Liu-Chen LY, Yang HH, Li S, Adams JU.
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
    [Abstract] [Full Text] [Related]

  • 23. Morphine withdrawal precipitated by specific mu, delta or kappa opioid receptor antagonists: a c-Fos protein study in the rat central nervous system.
    Le Guen S, Gestreau C, Besson JM.
    Eur J Neurosci; 2003 Jun; 17(11):2425-37. PubMed ID: 12814374
    [Abstract] [Full Text] [Related]

  • 24. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA, Heyman JS, Sheldon RJ, Koslo RJ, Porreca F.
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [Abstract] [Full Text] [Related]

  • 25. Naloxone rapidly evokes endogenous kappa opioid receptor-mediated hyperalgesia in naïve mice pretreated briefly with GM1 ganglioside or in chronic morphine-dependent mice.
    Crain SM, Shen KF.
    Brain Res; 2007 Sep 05; 1167():31-41. PubMed ID: 17692296
    [Abstract] [Full Text] [Related]

  • 26. Influence of ATP-dependent K+ channels on nicotine-induced inhibition of withdrawal in morphine-dependent mice.
    Zarrindast MR, Mohajeri S.
    Eur J Pharmacol; 2006 Dec 15; 552(1-3):90-8. PubMed ID: 17049514
    [Abstract] [Full Text] [Related]

  • 27. The contribution of supraspinal, peripheral and intrinsic spinal circuits to the pattern and magnitude of Fos-like immunoreactivity in the lumbar spinal cord of the rat withdrawing from morphine.
    Rohde DS, McKay WR, Chang DS, Abbadie C, Basbaum AI.
    Neuroscience; 1997 Sep 15; 80(2):599-612. PubMed ID: 9284361
    [Abstract] [Full Text] [Related]

  • 28. Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naïve and morphine-dependent mice.
    Divin MF, Holden Ko MC, Traynor JR.
    Eur J Pharmacol; 2008 Mar 31; 583(1):48-55. PubMed ID: 18275956
    [Abstract] [Full Text] [Related]

  • 29. Modification of mu-opioid agonist-induced locomotor activity and development of morphine dependence by diabetes.
    Kamei J, Ohsawa M, Saitoh A, Iwamoto Y, Suzuki T, Misawa M, Nagase H, Kasuya Y.
    J Pharmacol Exp Ther; 1995 Aug 31; 274(2):700-6. PubMed ID: 7636731
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Delta receptor involvement in morphine suppression of noxiously evoked activity of spinal WDR neurons in cats.
    Omote K, Kitahata LM, Nakatani K, Collins JG.
    Brain Res; 1991 Jul 19; 554(1-2):299-303. PubMed ID: 1657291
    [Abstract] [Full Text] [Related]

  • 32. Effect of propranolol on antinociceptive and withdrawal characteristics of morphine.
    Chipkin RE, Dewey WL, Harris LS, Lowenthal W.
    Pharmacol Biochem Behav; 1975 Jul 19; 3(5):843-7. PubMed ID: 1800
    [Abstract] [Full Text] [Related]

  • 33. Opioid delta-receptor involvement in supraspinal and spinal antinociception in mice.
    Heyman JS, Mulvaney SA, Mosberg HI, Porreca F.
    Brain Res; 1987 Sep 08; 420(1):100-8. PubMed ID: 2823970
    [Abstract] [Full Text] [Related]

  • 34. Dissociation of morphine withdrawal diarrhea and jumping in mice by the peripherally selective opioid antagonist SR 58002 C.
    Bianchetti A, Guidice A, Nava F, Manara L.
    Life Sci; 1986 Dec 15; 39(24):2297-303. PubMed ID: 3796195
    [Abstract] [Full Text] [Related]

  • 35. Spinal-supraspinal and intrinsic μ-opioid receptor agonist-norepinephrine reuptake inhibitor (MOR-NRI) synergy of tapentadol in diabetic heat hyperalgesia in mice.
    Christoph T, Schröder W, Tallarida RJ, De Vry J, Tzschentke TM.
    J Pharmacol Exp Ther; 2013 Dec 15; 347(3):794-801. PubMed ID: 24051022
    [Abstract] [Full Text] [Related]

  • 36. Chronic naloxone-induced supersensitivity affects neither tolerance to nor physical dependence on morphine at hypothalamus-pituitary-adrenocortical axis.
    Alcaraz C, Vargas ML, Milanés MV.
    Neuropeptides; 1996 Feb 15; 30(1):29-36. PubMed ID: 8868296
    [Abstract] [Full Text] [Related]

  • 37. Dependence and withdrawal following intracerebroventricular and systemic morphine administration: functional anatomy and behavior.
    Adams RE, Wooten GF.
    Brain Res; 1990 Jun 04; 518(1-2):6-10. PubMed ID: 2390728
    [Abstract] [Full Text] [Related]

  • 38. Use of a mu-antisense oligodeoxynucleotide as a mu opioid receptor noncompetitive antagonist in vivo.
    Chen XH, Liu-Chen LY, Tallarida RJ, Geller EB, de Riel JK, Adler MW.
    Neurochem Res; 1996 Nov 04; 21(11):1363-8. PubMed ID: 8947926
    [Abstract] [Full Text] [Related]

  • 39. The effects of naltrexone on the development of physical dependence on morphine.
    Bhargava HN.
    Eur J Pharmacol; 1978 Aug 01; 50(3):193-202. PubMed ID: 567585
    [Abstract] [Full Text] [Related]

  • 40. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.
    Wang D, Raehal KM, Lin ET, Lowery JJ, Kieffer BL, Bilsky EJ, Sadée W.
    J Pharmacol Exp Ther; 2004 Feb 01; 308(2):512-20. PubMed ID: 14600246
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.